Amended Current Report Filing (8-k/a)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
July 31, 2020 (August 1, 2013)
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of
||(Commission File Number)
||(IRS Employer Identification
Ludlow Avenue, Northvale, New Jersey 07647
of principal executive offices)
telephone number, including area code)
|(Former name or former
address, if changed since last report.)
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
pursuant to Rule 425 under the Securities Act (17 CFR
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
registered pursuant to Section 12(b) of the Act:
each exchange on which registered
|Common Stock, par
value $0.001 per share
by check mark whether the registrant is an emerging growth company
as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
growth company ☐
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
This Amendment No. 2 to the Current Report on Form 8-K (the “Form
8-K”), originally filed by Elite Pharmaceuticals, Inc. with the
Securities and Exchange Commission (the “Commission”) on August 5,
2013, and amended by Amendment No. 1 which was filed with the
Commission on August 30, 2018, is being filed solely for the
purposes of replacing Exhibit 10.1 with a new agreement that
contains no redactions.
Except as described above, No other changes have been made to the
Form 8-K or amendment No. 1 thereto. This Amendment No. 2 does not
otherwise amend, change, modify or update the disclosures set forth
in the Form 8-K as originally filed and does not otherwise reflect
events, results or developments that may have occurred, or facts
that have become known, after the original filing of the Form 8-K.
Accordingly, this Amendment No. 2 consists only of the cover page,
this Explanatory Note, Item 901 of the Form 8-K and the Signature
Item 9.01 Financial Statements and Exhibits.
The following exhibits are filed with this Current Report:
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this amendment no. 2 to the
report on Form 8-K to be signed on its behalf by the undersigned
hereunto duly authorized.
|Dated: July 31, 2020
||ELITE PHARMACEUTICALS, INC.
/s/ Carter Ward
||Carter Ward, CFO